AstraZeneca sets $80B revenue target, goal of 20 new drugs by 2030
The British-Swedish company on Tuesday laid out an ambitious plan to boost growth in its existing oncology, biopharma and rare disease portfolios, as well as launch 20 new medicines before the end of the decade.